Navigation Links
Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
Date:3/21/2011

CAMBRIDGE, Mass., March 21, 2011 /PRNewswire/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented new data for Replagal® (agalsidase alfa) in patients with Fabry disease, and VPRIV® (velaglucerase alfa for injection) in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' (ACMG) Annual Clinical Genetics Meeting, held in Vancouver, BC, from March 16-20, 2011.  

Data from clinical programs evaluating the safety of switching from Fabrazyme® (agalsidase beta) to Replagal and long-term safety and efficacy of switching from Cerezyme® (imiglucerase) to VPRIV were presented.

Preliminary data from Shire's Replagal study 059, an ongoing, multicenter, open-label clinical study, was presented for the first time.  This data, following 3 months of treatment, suggests that switching from Fabrazyme to Replagal 0.2 mg/kg every other week is generally well tolerated. This ongoing study includes 70 Fabry patients in the US under Shire's treatment protocol who were switched to Replagal during the continuing Fabrazyme supply shortage. The safety events observed in this study were similar to those seen historically in patients treated with Replagal.

Data from the 52 patients in Shire's VPRIV study 044, the extension study for studies 034 and 039, were presented. Data from study 058, Shire's treatment protocol in the US, in 205 type 1 Gaucher patients who switched from Cerezyme were also presented. Taken together, these studies include data from ongoing treatment in more than 250 patients, representing the largest and most comprehensive set of studies to date for Gaucher disease. This collection of long-term data (up to 2 years) adds to the growing body of clinical evidence which supports the use of VPRIV in patients who have previously been treated with imiglucerase.

<
'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
2. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
3. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
4. Reportlinker Adds Shire plc: PharmaVitae Profile
5. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
6. Shire plc - Statement re ProAmatine
7. Shire Proposes to Expand Specialist Gastrointestinal Portfolio
8. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
9. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
10. Shire plc Appoints Two New Board Directors
11. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 ViaDerma, Inc ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual carrier ... transfer of pharmaceutical active ingredients to penetrate the ... localized therapy. The transdermal delivery method also overcomes ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 This ... PHA, PBS, Starch Based Plastics, Regenerated Cellulose, PCL), ... Global Trends and Forecasts to 2019”, defines and ... analysis and forecast of its global volume and ... 54 Figures spread through 178 Slides and in-depth ...
(Date:10/25/2014)... 24, 2014 Oramed Pharmaceuticals Inc. ... focused on the development of oral drug delivery systems, ... will present at FireRock Capital,s Micro-Cap Conference. ... Conference ,Date: Tuesday, October 28, 2014 ,Time: 9:15am EST ... York City , About The ...
(Date:10/25/2014)... 24, 2014 ... has announced the addition of the  "The ... Other 2-D Nanomaterials "  report to their ... ,CNTs and graphene are the strongest, lightest ... with a performance-per-weight greater than any other ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4
... , Key ... assay, , ... of one assay component to an SPA Imaging Bead in order to ... antibody enable the immobilization of rabbit secondary antibodies during the assay. The ...
... TE 70, TE 77, TE 70 PWR, TE 77 PWR , ... transfer results using low current and voltage with a minimal amount of buffer. ... with and without built-in power supplies to give maximum flexibility , ... from polyacrylamide gels in less than 1 h , ...
... Key words: ... LC-MS/MS • reversed-phase chromatography (RPC) • strong cation exchange (SCX) ... , ... brain tissue. The trypsin-digested tissue was separated by strong cation ...
Cached Biology Technology:Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells 2Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells 3Utilization of Donkey Anti-Rabbit PS SPA Imaging Beads in the quantitative measurement of cAMP in cells 4ECL Semi-dry Blotters 22D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 22D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 32D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 42D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 52D-LC analysis of phosphopeptides in brain tissue using Ettan MDLC and Finnigan LTQ 6
(Date:10/17/2014)... for the first time how bacteria can grow directly ... the opportunity to get tremendous insights into bacteria behavior ... discovered the bacterial growth in chronic lung infections among ... by the immune cells. The researchers discovered the immune ... bacteria, forcing the bacteria to switch to a much ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... Taiwan and Japan and led by University of Illinois scientists ... times more active in killing tumor cells than similar drugs ... this week in the Journal of the American Chemical ... of drugs called bisphosphonates. These compounds were originally developed to ...
... Researchers at the Tulane University School of Medicine, ... protease inhibitors (PIs), such as nelfinavir included in ... treatment of HIV-1 patients, induce deleterious effects on ... They report a significant decrease in the levels ...
... researcher has discovered dozens of species of jumping spiders that ... section of the evolutionary tree previously thought to be sparse. ... world except Antarctica. Capable of jumping 30 times their body ... households. They come in many shapes and sizes, some resembling ...
Cached Biology News:New drug agent knocks out multiple enzymes in cancer pathway 2HIV-1 protease inhibitor induced oxidative stress in pancreatic B-cells: thymoquinone protection 2New species of spiders discovered by UBC scientist in Papua New Guinea 2